Bradykinin Receptor Antagonists

Compounds and drugs that inhibit ligand binding or cellular signaling by BRADYKININ RECEPTORS.

Also Known As:

Bradykinin Antagonists; Bradykinin Receptor Blockers; Bradykinin Receptor Inhibitors; Antagonist, Bradykinin; Antagonist, Bradykinin Receptor; Antagonists, Bradykinin; Antagonists, Bradykinin Receptor; Blocker, Bradykinin Receptor; Inhibitor, Bradykinin Receptor; Inhibitors, Bradykinin Receptor; Receptor Antagonist, Bradykinin; Receptor Antagonists, Bradykinin; Receptor Blocker, Bradykinin; Receptor Blockers, Bradykinin; Receptor Inhibitor, Bradykinin; Receptor Inhibitors, Bradykinin; Bradykinin Antagonist; Bradykinin Receptor Antagonist; Bradykinin Receptor Blocker; Bradykinin Receptor Inhibitor

Networked: 155 relevant articles (10 outcomes, 19 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Bradykinin Receptor Antagonists: 155
      - Bradykinin B1 Receptor Antagonists: 11
      - Bradykinin B2 Receptor Antagonists: 8

Experts

1.	Gera, Lajos: 8 articles (08/2014 - 04/2002)
2.	Stewart, John M: 7 articles (12/2010 - 04/2002)
3.	Chan, Daniel C: 4 articles (08/2005 - 05/2002)
4.	Helfrich, Barbara: 4 articles (05/2004 - 04/2002)
5.	Stewart, J M: 4 articles (01/2003 - 06/2000)
6.	Bujalska, Magdalena: 3 articles (07/2009 - 01/2008)
7.	Bunn, Paul A: 3 articles (08/2005 - 05/2002)
8.	Simkeviciene, Vitalija: 3 articles (08/2005 - 12/2002)
9.	Taraseviciene-Stewart, Laimute: 3 articles (08/2005 - 04/2002)
10.	York, Eunice J: 3 articles (08/2005 - 12/2002)

Related Diseases

1.	Angioedema 04/01/2013 - "There is limited experience using bradykinin receptor blockers and fresh frozen plasma (FFP) as a treatment modality for ACEI-induced angioedema. " 01/01/2018 - "Conclusion The efficacy of treatment of ACEI-induced angioedema with bradykinin antagonists, kallikrein inhibitor, and C1 inhibitor warrants further study. " 03/01/2015 - "The role of icatibant-the B2 bradykinin receptor antagonist-in life-threatening laryngeal angioedema in the ED." 09/01/2019 - "Specific clinical signs may point to HAE as opposed to histaminergic angioedema: the typical prolonged development of angioedema over time, positive family history, a lack of response to antihistamines and steroids and response to bradykinin antagonists are typical signs of HAE. " 01/01/2023 - "Recent advances in the understanding of the pathophysiology of angioedema have led to the development of targeted therapies, such as monoclonal antibodies, bradykinin receptor antagonists, and complement inhibitors, which promise to improve clinical outcomes in patients with this challenging condition. "
2.	Neoplasms (Cancer) 08/01/2014 - "Bradykinin antagonists and thiazolidinone derivatives as new potential anti-cancer compounds." 01/01/2003 - "In the xenotransplants certain bradykinin antagonists showed higher potency than standard anti-cancer drugs, without evident toxicity to the hosts. " 01/01/2003 - "Bradykinin antagonists as anti-cancer agents." 09/01/2014 - "The involvement of the KKS in malignant prostate pathology supports on-going exploration of bradykinin receptor antagonists as target candidates in the development of alternate approaches to cancer therapy." 08/01/2005 - "Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists."
3.	Hereditary Angioedemas 07/01/2023 - "Therapeutic management of hereditary angioedema first consists in treating severe attacks with a selective B2 bradykinin receptor antagonist or a C1 inhibitor concentrate. " 09/01/2019 - "International guideline-recommended on-demand treatments for hereditary angioedema (HAE) include: C1-esterase inhibitor (plasma-derived or recombinant), or bradykinin-receptor antagonists. " 01/01/2012 - "Icatibant, a first-in-class B2 bradykinin receptor antagonist, appears to have a favorable efficacy and safety profile for the treatment of acute attacks of hereditary angioedema in adults. " 08/01/2011 - "The clinical bottom line is there is promising evidence for the use of the bradykinin receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema." 08/05/2010 - "Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema."
4.	Asthma (Bronchial Asthma) 10/01/1998 - "Thus, bradykinin receptor antagonists may have therapeutic potential against asthma. " 01/01/1992 - "The potential role of bradykinin antagonists in the treatment of asthma." 04/01/2012 - "Collectively, these findings indicate that skullcapflavone II, a potential bradykinin antagonist, reduced the major pathophysiological features of allergic asthma, at least in part by acting on TGF-β1/Smad signaling pathways. " 04/01/2010 - "In the present study the effects of bradykinin receptor antagonists were investigated in a murine model of asthma using BALB/c mice immunized with ovalbumin/alum and challenged twice with aerosolized ovalbumin. " 02/01/1999 - "Our study suggests a possible implication of these mechanisms in asthma associated with gastroesophageal acid reflux and a potential therapeutic role of tachykinin and bradykinin antagonists."
5.	Inflammation (Inflammations) 01/01/1993 - "Bradykinin antagonists show great promise for development of new drugs for inflammation." 08/01/1994 - "The bradykinin antagonist could thus have a potential for a clinical use against pain associated with periodontal inflammation." 07/21/1992 - "Pain and inflammation evoked in human skin by bradykinin receptor antagonists." 01/01/1997 - "5. The use of bradykinin receptor antagonists in vivo has led to an appreciation of the involvement of bradykinin receptors in inflammation. " 06/01/1994 - "As well as having direct relevance to a known pathological condition,collagenase-induced paw oedema could prove to be a useful model in inflammation research and in the investigation of bradykinin antagonists. "

Related Drugs and Biologics

1.	icatibant
2.	Bradykinin
3.	NPC 567
4.	Kallikreins (Kallikrein)
5.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
6.	beta-Endorphin (Endorphin, beta)
7.	Nitric Oxide Synthase (NO Synthase)
8.	Lactic Acid (Lactate)
9.	Complement C1 (Complement 1)
10.	Analgesics (Analgesic Drugs)

Related Therapies and Procedures

1.	Therapeutics
2.	Intravenous Injections
3.	Drug Therapy (Chemotherapy)
4.	Secondary Prevention
5.	Subcutaneous Infusions